, Volume 8, Issue 5, pp 309–318 | Cite as

On certain psychopharmacological and physiological differences between schizophrenic and normal persons

  • Conan Kornetsky
  • Allan F. Mirsky


The schizophrenic patient is generally regarded to be less responsive than the normal person to many drugs as well as to certain nonpharmacological conditions. Evidence is presented that there is not an attenuated response in the schizophrenic with all centrally acting drugs. The schizophrenic may in fact be more responsive than the normal person to some nonpharmacological conditions. These studies are reviewed and a neuropsychological hypothesis proffered which may account for some of the differences between the normal and the schizophrenic.

The hypothesis states that the schizophrenic patients are in a state of chronic hyperarousal. This results from dysfunction in those areas of the brain concerned with the maintainence of arousal, and attention, i. e. the brain stem reticular activating system.


Brain Stem Schizophrenic Patient Normal Person Physiological Difference Neuropsychological Hypothesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bradley, P. B.: The central action of certain drugs in relation to the reticular formation of the brain. (In: Reticular Formation of the Brain, H. H. Jasper et al. Eds.) Boston: Little Brown 1958.Google Scholar
  2. Chessick, R. D., C. A. Haertzen, and A. Wikler: Tolerance to LSD-25 in schizophrenic subjects. Arch. gen. Psychiat. 10, 653–658 (1964).Google Scholar
  3. Davis, P. A., and H. Davis: The electroencephalograms of psychotic patients. Amer. J. Psychiat. 95, 1007–1025 (1939).Google Scholar
  4. Duffy, E.: The psychological significance of the concept of “arousal” or “activation”. Psychol. Rev. 64, 265–275 (1957).Google Scholar
  5. Fedio, P., A. F. Mirsky, W. J. Smith, and D. Parry: Reaction time and EEG activation in normal and schizophrenic subjects. Electroenceph. clin. Neurophysiol. 13, 923–926 (1961).Google Scholar
  6. Goldstein, L., H. B. Murphree, A. Sugerman, C. C. Pfeiffer, and E. H. Jenney: Quantitative electroencephalographic analysis of naturally occuring (schizophrenic) and drug-induced psychotic states in human males. Clin. Pharm. Ther. 4, 10–21 (1963).Google Scholar
  7. Gromoll, H. F.: The process-reactive dimension of schizophrenia in relation to cortical activation and arousal. Unpublished Ph. D. Thesis; University of Illinois, Urbana 1961.Google Scholar
  8. Hill, D.: Electroencephalogram in schizophrenia. (In: Schizophrenia: somatic aspects., D. Richter, Ed.) London, New York: Pergamon Press 1957.Google Scholar
  9. Jasper, H. H., C. P. Fitzpatrick, and H. Solomon: Analogies and opposites in schizophrenia and epilepsy. Electroencephalographic and Clinical Studies. Amer. J. Psychiat. 95, 835–851 (1939).Google Scholar
  10. Killam, K. F., and E. K. Killam: Drug action on pathways involving the reticular formation. (In: Reticular Formation of the Brain, H. H. Jasper et al., Eds.) Boston: Little Brown 1958.Google Scholar
  11. Kornetsky, C., M. Pettit, R. Wynne, and E. V. Evarts: A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. J. ment. Sci. 105, 190–198 (1959).Google Scholar
  12. Krus, D. M., S. Wapner, H. Freeman, and T. M. Casey: Differential behavior responsivity to LSD-25. Arch. gen. Psychiat. 8, 557–563 (1963).Google Scholar
  13. Latz, A., and C. Kornetsky: A comparison of the effects of benzquinamide with those of chlorpromazine and secobarbital on a number of performance tests in chronic schizophrenics. Pharmacologist 5, 233 (1964).Google Scholar
  14. Liberson, W. T.: Functional electroencephalography in mental disorders. Dis. nerv. Syst. 5, 357–364 (1944).Google Scholar
  15. Malmo, R. A.: Activation: a neuropsychological dimension. Psychol. Rev. 66, 367–386 (1959).Google Scholar
  16. Mirsky, A. F., and C. Kornetsky: On dissimilar effects of drugs on the digit symbol substitution and continuous performance tests. Psychopharmacologia (Berl.) 5, 161–177 (1964).Google Scholar
  17. Modell, W., and A. E. Hussar: Dextroamphetamine sulfate and the eating and sleeping patterns of schizophrenics. J. Amer. med. Ass. 193, 275–278 (1965).Google Scholar
  18. Orzack, M. H., and C. Kornetsky: Attention dysfunction in chronic schizophrenia. Arch. gen. Psychiat. (in press) (1965).Google Scholar
  19. Richter, D.: Biochemical aspects of schizophrenia. (In: Schizophrenia: somatic aspects, D. Richter, Ed.) London, New York: Pergamon Press 1957.Google Scholar
  20. Rosvold, H. E., A. F. Mirsky, L. Sarason, E. D. Bransome jr., and L. H. Beck: A continuous performance test of brain damage. J. cons. Psychol. 20, 343–350 (1956).Google Scholar
  21. Shakow, D.: The nature of deterioration in schizophrenic conditions. Nerv. dis. monogr. Ser. 70, 1–80 (1946).Google Scholar
  22. Stammeyer, E. C.: The effects of distraction on performance in schizophrenic, psychoneurotic, and normal individuals. Dissertation, Washington, D. C.: The Catholic University of America Press 1961.Google Scholar
  23. Vates, T., and C. Kornetsky: A comparison of some physiological changes in normal and schizophrenic subjects twelve hours after chlorpromazine administration. p. 35 Abstracts of Fall Meeting: American Society for Pharmacology and Experimental Therapeutics 1958.Google Scholar
  24. Venables, P. H.: Input dysfunction in schizophrenia. (In: Progress in experimental personality research, B. A. Maher, Ed.) New York: Academic Press 1964.Google Scholar
  25. —, and J. K. Wing: Levels of arousal and the sub-classification of schizophrenia. Arch. gen. Psychiat. 7, 114–119 (1962).Google Scholar
  26. Wechsler, D.: The measurement of adult intelligence, Ed. 3. Baltimore: Williams and Wilkins Co. 1944.Google Scholar

Copyright information

© Springer-Verlag 1965

Authors and Affiliations

  • Conan Kornetsky
    • 1
  • Allan F. Mirsky
    • 1
  1. 1.Department of Pharmacology and the Division of PsychiatryBoston University School of Medicine, Boston University Medical CenterBoston

Personalised recommendations